Skip to main content

ULTRA-DD

Innovative Medicines Initiative LogoEfpia logoEuropean Commission Research and Innovation logo

Search

  • Overview
    • Objectives and disease focus
    • Deliverables
      • Executive Summary 2020 Report
      • Executive Summary 2019 Report
      • Executive Summary 2018 Report
    • Organisation
      • Scientific Committee
      • Leadership
    • Participants
    • News
    • Contact
  • Tissue Platforms
    • Diseases
    • Cell Assay Datasets
  • Probes
    • Chemical Probes
    • Biological probes
  • Antibodies
  • Structures
  • ChromoHub
  • Publications

Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes

  • Read more about Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes

Mehnert, M., Ciuffa, R., Frommelt, F., Uliana, F., van Drogen, A., Ruminski, K., . . . Aebersold, R. (2020). Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes. Nat Commun, 11(1), 3563.

Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor-stroma drug targeting

  • Read more about Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor-stroma drug targeting

Kock, A., Bergqvist, F., Steinmetz, J., Elfman, L. H. M., Korotkova, M., Johnsen, J. I., . . . Larsson, K. (2020). Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor-stroma drug targeting. Faseb j, 34(8), 11101-11114.

A Global Screen for Assembly State Changes of the Mitotic Proteome by SEC-SWATH-MS

  • Read more about A Global Screen for Assembly State Changes of the Mitotic Proteome by SEC-SWATH-MS

Heusel, M., Frank, M., Köhler, M., Amon, S., Frommelt, F., Rosenberger, G., ... Aebersold, R. (2020). A Global Screen for Assembly State Changes of the Mitotic Proteome by SEC-SWATH-MS. Cell Syst, 10(2), 133-155.e136.

Proteomics-Based Characterization of miR-574-5p Decoy to CUGBP1 Suggests Specificity for mPGES-1 Regulation in Human Lung Cancer Cells

  • Read more about Proteomics-Based Characterization of miR-574-5p Decoy to CUGBP1 Suggests Specificity for mPGES-1 Regulation in Human Lung Cancer Cells

Emmerich, A. C., Wellstein, J., Ossipova, E., Baumann, I., Lengqvist, J., Kultima, K., . . . Saul, M. J. (2020). Proteomics-Based Characterization of miR-574-5p Decoy to CUGBP1 Suggests Specificity for mPGES-1 Regulation in Human Lung Cancer Cells. Front Pharmacol, 11, 196

Kinase Interaction Network Expands Functional and Disease Roles of Human Kinases

  • Read more about Kinase Interaction Network Expands Functional and Disease Roles of Human Kinases

Buljan, M., Ciuffa, R., van Drogen, A., Vichalkovski, A., Mehnert, M., Rosenberger, G., . . . Gstaiger, M. (2020). Kinase Interaction Network Expands Functional and Disease Roles of Human Kinases. Mol Cell, 79(3), 504-520.e509

Anti-Inflammatory Properties of Chemical Probes in Human Whole Blood: Focus on Prostaglandin E(2) Production

  • Read more about Anti-Inflammatory Properties of Chemical Probes in Human Whole Blood: Focus on Prostaglandin E(2) Production

Bergqvist, F., Sundström, Y., Shang, M. M., Gunnarsson, I., Lundberg, I. E., Sundström, M., . . . Berg, L. (2020). Anti-Inflammatory Properties of Chemical Probes in Human Whole Blood: Focus on Prostaglandin E(2) Production. Front Pharmacol, 11, 613

NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency

  • Read more about NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency

Marques, J. G., Gryder, B. E., Pavlovic, B., Chung, Y., Ngo, Q. A., Frommelt, F., . . . Schäfer, B. W. (2020). NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency. Elife, 9.

Designing custom CRISPR libraries for hypothesis-driven drug target discovery

  • Read more about Designing custom CRISPR libraries for hypothesis-driven drug target discovery

Iyer, V., Jiang, L., Shen, Y., Boddul, S., Panda, S., Kasza, Z., ... Wermeling, F. (2020). Designing custom CRISPR libraries for hypothesis-driven drug target discovery. Computational And Structural Biotechnology Journal, 18, 2237-2246.

Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300

  • Read more about Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300

Williams, L., McCann, F., Cabrita, M., Layton, T., Cribbs, A., Knezevic, B., ... Nanchahal, J. (2020). Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300. Proceedings Of The National Academy Of Sciences, 117(34), 20753-20763.

IL-4 controls activated neutrophil FcγR2b expression and migration into inflamed joints.

  • Read more about IL-4 controls activated neutrophil FcγR2b expression and migration into inflamed joints.

Panda, S., Wigerblad, G., Jiang, L., Jiménez-Andrade, Y., Iyer, V., Shen, Y., ... Wermeling, F. (2020). IL-4 controls activated neutrophil FcγR2b expression and migration into inflamed joints. Proceedings Of The National Academy Of Sciences, 117(6), 3103-3113.

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to 2020
The ULTRA-DD project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement n° [115766], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This website reflects only the author’s views and neither IMI nor the European Commission is liable for any use that may be made of the information contained therein.
This website is licensed under a CC-BY licence | Accessibility